Αρχική World News FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for... World News FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer Από Ogkologos - 30 Μαΐου, 2025 934 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Darolutamide Delays the Spread of Some Prostate Cancers 15 Μαρτίου, 2019 Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... 20 Ιουλίου, 2021 Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... 30 Οκτωβρίου, 2020 Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will... 15 Μαρτίου, 2019 Φόρτωση περισσοτέρων HOT NEWS 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... Factors Associated with COVID-19 Severity Among Patients with Cancer Reflecting On My Time As the Cancer.Net Editor in Chief Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations